GENETIC ALTERATIONS OF ANDROGEN RECEPTOR GENE AND P53 BY FLUORESCENCE, IN SITU HYBRIDIZATION AND IMMUNODETECTION OF BCL-2 IN PROSTATIC INTRAEPITHELIAL NEOPLASIA AND CARCINOMA

Yıl 2001, Cilt: 14 Sayı: 4, 207 - 212, 03.12.2016

Handan Kaya İlter Güney Çiğdem Çelikel Levent Türkeri Atıf Akdaş Sevgi Küllü

Öz

Objective: p53 and androgen receptor gene changes and bcl-2 expression in prostatic intraepithelial neoplasia (PIN) and adenocarcinoma were studied. The genetic associations of PIN and adenocarcinoma as detected by FISH and immunohistochemistry were discussed.
Material and Method: The study group consisted of 18 prostate cancer cases treated by radical prostatectomy. The p53 and androgen receptor gene changes at chromosomal level were studied using the FISH technique. Also, immunohistochemistry was used to search for bcl-2 expression.
Results: Of the 18 cases studied by FISH, it was found that in benign areas AR gene amplification was 78% (14/18) and 100% disomy with wild type p53, in PIN areas AR gene amplification was 33% (6/18), p53 amplification 28% (5/18), in carcinomas AR gene amplification was 39% (7/18), and p53 amplification 28% (5/18). We observed the bcl-2 immunexpression mainly in basal ductal cells in benign, PIN and carcinoma areas.
Conclusion: The results of our study suggest that AR gene amplification is significantly higher in benign areas compared to carcinomatous foci and that the presence of AR gene amplification is associated with the tumour stage. PIN is the most likely precursor of prostatic carcinoma.
Key Words: Androgen receptor gene, p53, FISH, Prostate carcinoma

Kaynakça

• Bostwick DG. The pathology of incidental carcinoma. Cancer Surveys 1995;23:7-17.
• Humphrey PA, Walther PJ. Adenocarcinoma of the prostate. Am J Clin Pathol 1993; 100:256- 269.
• Bostwick DG. High grade prostatic
• intraepthelial neoplasia. Cancer
• :75:1823-1826.
• Barretton GB, Vogt T, Blasenbreu X, Lôhrs U.
• Comparison of DHA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: an image
• cytometric study. Hum Pathol 1994:25:506- 513.
• Qi-Long L, Abel P, Poster C, Lalani E. bcl-2 role in epithelial differentiation and oncogenesis. Hum Pathol 1996:27:102-110.
• Colombel !4, Symmans P, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol 1993;143:390-400.
• Taniguchi J, Moriyama H, Puri mo to S, Pameyama S, Paw a be P. Histochemical detection of intranuclear DHA fragmentation and its relation to the expression of be 1-2 oncoprotein in human prostatic cancer. Br J Urol 1996;77:719-723.
• Arnold JL. Tumor suppressor genes. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The molecular basis of cancer. Philadelphia: W.B. Saunders, 1995:86-101.
• Persons DL, Takai P, Gibney DJ, Patzmann JA, Lieber MM, Jenkins RB. Comparison of fluorescence in situ hybridization with flow cytometry and static image analysis in ploidy analysis of paraffin embedded prostate adenocarcinoma. Hum Pathol 1994;25:678- 683.
• Handan Kaya, el al
• Brown JA, Alcaraz A, Kakahashi S, Persons DL, Lieber MPI, Jenkins RB. Chromosomal aneusomies detected by fluorescence in situ hybridization analysis in clinically localised prostate carcinoma. J Urol ¡994,152:1157- 1 162.
• C^ian J, Bostwick DG, Takashi S, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995; 15:5408-5414.
• Wilding G. Endocrine control of prostate cancer. Cancer Surveys 1995:23:45-62.
• Qian J, Jenkins RB, Bostwick DG. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. J Pathol 1999:35:479-483.
• Takeda PI, Akakura R, Masai M, Akimoto S, Yatani R. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 1996:77:934-940.
• Mydlo Jfl, Krai JG, Volpe M, Axotis C, Macchia RJ, Pertsvhuk LP. An analysis of microvessel density, androgen receptor, p53 and Her- 2/neu expression and Gleason score in prostate cancer. Eur Urol 1998:34:426-432.
• Koivista PA, Plelin P1J. Androgen receptor gene amplification increases tissue PSA protein expression in hormone - refractory prostate carcinoma. J Pathol 1999;189:219-223.
• Visokorpi T, flyytinen E, Kovisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer, nature Genet 1995;9:401-406.
• Koivisto PA, Kononen J, Palm berg C, et at. Androgen receptor gene amplification: a possible mechanism for failure of androgen deprivation therapy in prostate cancer. Cancer Res 199 7;5:314-319.
• Miyoshi Y, Uemura fl, Eujinami K, et al. Fluorescence in situ hybridization evaluation of c-mye and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000,15:225-232.
• Koivista PA, Rantala I. Amplification of the androgen receptor gene is associated with p53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 1999;187:237-241.
• Effert PJ, Ueubauer A, Walther PJ, Liu ET. Alterations of the p53 gene are associated with the progression of a prostate carcinoma. J Urol 1992,147:789.
• Schechte fl, Lenk SK, Lôning T, et al. P53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer. Eur Urol 1998;34:433-440.
• Bhaskar KS, Kallakury S, Figge J, et al. Association of p53 immunoreactivity with high Gleason tumour grade in prostatic adenocarcinoma. Hum Pathol 1994;25:92-97.
• Me Donnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene be I -2 in the prostate and its association with emergence of androgen independent prostate cancer. Cancer Res 1992;52:6940-6944.
• ColombeI M, Symmans F, Gill S, et al. Detection of the apoptosis suppressing ancoprotein be 1-2 in hormone refractory human prostate cancers. Am J Pathol 1993;143:394-400.
• Krajewska M, Krajewski S, Epstein JL, et al. Immunohistochemical analysis of be I-2, bax, bcl-x, and mcl-l expression in prostate cancers. Am J Pathol 1996; 148:1567-1569.
• ITupponen HH, Kokkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone refractory recurrent prostate carcinomas. Am J Pathol 1998; 153:141-148.
• Haussier O, Epstein Jl. Amin MB, Heitz PU, Hailemariam S. Cell proliferation, apoptosis, oncogene and tumour suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia and cancer. Hum Pathol 1999:30:1077-1086.
• Theoderescu D, Broder SR, Boyd J, Mills SE, Frierson HF. p53, be 1-2 and retinoblastoma proteins as long term prognostic markers in localised carcinoma of the prostate. J Urol 1997;158:131-137.